BTK抑制剂突围自身免疫病

药事纵横
Mar 09

2月8日,罗氏公布了Fenebrutinib对比Ocrevus(奥瑞利珠单抗)治疗原发性进行型多发性硬化症(PPMS)的III期FENtrepid研究的最新数据。结果显示,Fenebrutinib在降低残疾进展方面达到主要非劣效性终点,与Ocrevus相比,cCDP12衡量残疾进展风险降低了12%。在所有患者亚组中均观察到cCDP12的一致治疗效果,其中在9HPT分量表上效果最显著,风险降低26%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10